These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20351182)

  • 21. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
    He T; Tang C; Xu S; Moyana T; Xiang J
    Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
    Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
    J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
    Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
    J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells.
    Ke Y; Kapp JA
    J Immunol; 1996 Feb; 156(3):916-21. PubMed ID: 8558017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.
    You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY
    Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defective CD8+ T cell activation and cytolytic function in the absence of LFA-1 cannot be restored by increased TCR signaling.
    Shier P; Ngo K; Fung-Leung WP
    J Immunol; 1999 Nov; 163(9):4826-32. PubMed ID: 10528183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
    Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L.
    Buonocore S; Haddou NO; Moore F; Florquin S; Paulart F; Heirman C; Thielemans K; Goldman M; Flamand V
    J Leukoc Biol; 2008 Sep; 84(3):713-20. PubMed ID: 18567840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell precursor frequency differentially affects CTL responses under different immune conditions.
    Ye Z; Ahmed KA; Huang J; Xie Y; Munegowda MA; Xiang J
    Biochem Biophys Res Commun; 2008 Mar; 367(2):427-34. PubMed ID: 18178159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
    Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The degree of CD8 dependence of cytolytic T cell precursors is determined by the nature of the T cell receptor (TCR) and influences negative selection in TCR-transgenic mice.
    Auphan N; Curnow J; Guimezanes A; Langlet C; Malissen B; Mellor A; Schmitt-Verhulst AM
    Eur J Immunol; 1994 Jul; 24(7):1572-7. PubMed ID: 8026519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional conservation of Notch1 and Notch2 intracellular domains.
    Kraman M; McCright B
    FASEB J; 2005 Aug; 19(10):1311-3. PubMed ID: 15897231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.